Status:
COMPLETED
Predicting the Response of Patients With Rheumatoid Arthritis to Treatment With Genetically Engineered Biological Drugs and Janus (JAK) Kinase Inhibitors
Lead Sponsor:
Institute of Biomedical Chemistry, Russia
Collaborating Sponsors:
Moscow Regional Research and Clinical Institute (MONIKI)
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
Brief Summary
Rheumatoid arthritis (RA) is a chronic disease affecting about 1% of the worldwide population. RA is characterized by inflammation of the synovial membrane joints, which can lead to the destruction of...
Eligibility Criteria
Inclusion
- Patients diagnosed with rheumatoid arthritis after therapy.
Exclusion
- Patients with cancer and infectious diseases
Key Trial Info
Start Date :
January 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06177405
Start Date
January 15 2021
End Date
November 1 2023
Last Update
December 20 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IBMC
Moscow, Russia